Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-022644

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — President and CEO · Director
Period of report
Sep 25, 2017
Accepted (ET)
Sep 27, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF2Aug 23, 2017G41,075$0.00D10,328IBy GRAT 1
Common Stock, $0.0001 par valueF3Aug 23, 2017G41,075$0.00A41,075IBy Child's Trust 1
Common Stock, $0.0001 par valueF2Aug 23, 2017G10,328$0.00D0IBy GRAT 1
Common Stock, $0.0001 par valueF4Aug 23, 2017G10,328$0.00A10,328IBy Family Trust
Common Stock, $0.0001 par valueF6Aug 23, 2017G41,075$0.00D10,328IBy Wife's GRAT 1
Common Stock, $0.0001 par valueF7Aug 23, 2017G41,075$0.00A41,075IBy Child's Trust 2
Common Stock, $0.0001 par valueF6Aug 23, 2017G10,328$0.00D0IBy Wife's GRAT 1
Common Stock, $0.0001 par valueF4Aug 23, 2017G10,328$0.00A20,656IBy Family Trust
Common Stock, $0.0001 par valueF9,F10Sep 25, 2017S100,000$25.0079D515,308D
Common Stock, $0.0001 par valueF11holding———14,447IBy GRAT 2
Common Stock, $0.0001 par valueF12holding———14,447IBy Wife's GRAT 2

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses